Watching Recursion Pharmaceuticals; Hearing Berenberg Reiterates Buy Rating, $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Berenberg has reiterated its buy rating for Recursion Pharmaceuticals, with a price target of $33. The news may influence the stock's performance in the short term.
July 12, 2023 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Recursion Pharmaceuticals' stock may see positive movement following Berenberg's reiterated buy rating and $33 price target.
Analyst ratings and price targets can significantly influence a stock's performance. Berenberg's reiterated buy rating and price target of $33 for Recursion Pharmaceuticals indicates a positive outlook for the company, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100